An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Health Policy(2018)
Abstract
•In the payer analysis, nivolumab’s NMB was −$1031 if QALYs were valued at $150,000.•Nivolumab had a positive NMB when value was measured from a societal perspective.•Half of nivolumab’s value was omitted under traditional payer analysis.
MoreTranslated text
Key words
Lung neoplasms,Canada,Cost-effectiveness analysis,Net monetary benefit
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined